Kazutaka Saito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5870344/publications.pdf

Version: 2024-02-01

197 papers 4,192 citations

35 h-index 56 g-index

207 all docs

207 docs citations

207 times ranked 4598 citing authors

#	Article	IF	CITATIONS
1	Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology, 2022, 163, 164-176.	1.0	5
2	Differences in CRP and De Ritis ratio predictive abilities of cancer specific survival between ethnic groups Journal of Clinical Oncology, 2022, 40, 394-394.	1.6	O
3	Impact of age on functional decline following radical nephrectomy: Analysis of the International Marker Consortium for Renal Cancer (INMARC) Journal of Clinical Oncology, 2022, 40, 395-395.	1.6	O
4	Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis Journal of Clinical Oncology, 2022, 40, 325-325.	1.6	0
5	Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort. Clinical Genitourinary Cancer, 2022, 20, e276-e282.	1.9	1
6	Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non–muscle-invasive Bladder Cancer. European Urology Focus, 2021, 7, 366-372.	3.1	7
7	Outcomes of gasless laparoendoscopic singleâ€port partial nephrectomy in 356 consecutive patients: Feasibility of a clampless and sutureless technique. International Journal of Urology, 2021, 28, 302-307.	1.0	6
8	Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunology, Immunotherapy, 2021, 70, 657-665.	4.2	20
9	Elevated preoperative Câ€reactive protein is associated with renal functional decline and nonâ€cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC). BJU International, 2021, 127, 311-317.	2.5	11
10	Potential of Perfusion Magnetic Resonance Imaging to Predict Residual Renal Function after Radical Nephroureterectomy. Urologia Internationalis, 2021, 105, 507-513.	1.3	1
11	Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab., 2021, 9, e001564.		34
12	Nonmetastatic castrationâ€resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy. IJU Case Reports, 2021, 4, 228-230.	0.3	1
13	Nonuse of antimicrobial prophylaxis in clean surgeries for adrenal and renal tumors: Results of the riskâ€based strategy in 1362 consecutive patients. International Journal of Urology, 2021, 28, 1032-1038.	1.0	O
14	Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer. Brachytherapy, 2021, 20, 842-848.	0.5	5
15	Preoperative Elevation of C-Reactive Protein Is a Predictor for Adverse Oncologic Survival Outcomes for Renal Cell Carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC). Clinical Genitourinary Cancer, 2021, 19, e206-e215.	1.9	13
16	Impact of Bladder Neck Involvement on Recurrence in Patients With Non–muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model. Clinical Genitourinary Cancer, 2020, 18, e62-e70.	1.9	6
17	Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC). Clinical Genitourinary Cancer, 2020, 18, 111-116.e1.	1.9	13
18	METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e391-e396.	1.9	12

#	Article	IF	CITATIONS
19	Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy. Clinical Genitourinary Cancer, 2020, 18, 268-273.e2.	1.9	4
20	The Diagnostic Accuracy of Testicular Torsion by Doctors on Duty Using Sonographic Evaluation with Color Doppler. American Journal of Men's Health, 2020, 14, 155798832095300.	1.6	9
21	SRY-Positive 46, XX Testicular Disorder of Sexual Development With Leydig Cell Tumor. American Journal of Men's Health, 2020, 14, 155798832097007.	1.6	5
22	Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. Cancer Medicine, 2020, 9, 8355-8363.	2.8	15
23	Longitudinal changes in patientâ€reported outcomes after artificial urinary sphincter implantation. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 240-244.	1.3	4
24	Contact with renal sinus is associated with poor prognosis in surgically treated pT1 clear cell renal cell carcinoma. International Journal of Urology, 2020, 27, 657-662.	1.0	4
25	Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome. International Journal of Urology, 2020, 27, 395-400.	1.0	6
26	Application of virtual reality in patient explanation of magnetic resonance imaging–ultrasound fusion prostate biopsy. International Journal of Urology, 2020, 27, 471-472.	1.0	8
27	Incidence and Risk Factors of Hypertension Following Partial Nephrectomy in Patients With Renal Tumors: A Cross-sectional Study of Postoperative Home Blood Pressure and Antihypertensive Medications. Clinical Genitourinary Cancer, 2020, 18, e619-e628.	1.9	4
28	Treatmentâ€induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropinâ€releasing hormone antagonists or agonists. International Journal of Urology, 2020, 27, 354-355.	1.0	3
29	Feasibility and outcomes of selective tetramodal bladderâ€preservation therapy in elderly patients with muscleâ€invasive bladder cancer. International Journal of Urology, 2020, 27, 236-243.	1.0	7
30	Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusionâ€weighted magnetic resonance imaging. International Journal of Urology, 2020, 27, 599-604.	1.0	2
31	Value of extraâ€target prostate biopsy for the detection of magnetic resonance imagingâ€missed adverse pathology according to the Prostate Imaging Reporting and Data System scores: Spatial analysis using magnetic resonance–ultrasound fusion images. International Journal of Urology, 2020, 27, 760-766.	1.0	4
32	Association of De Ritis Ratio and Neutrophil Lymphocyte Ratio with renal functional decline and all-cause mortality in renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 741-741.	1.6	1
33	Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study Journal of Clinical Oncology, 2020, 38, 666-666.	1.6	0
34	Impact of oncological versus nononcological on survival outcomes in African Americans with renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 749-749.	1.6	0
35	Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor. International Journal of Radiation Oncology Biology Physics, 2019, 105, 376-381.	0.8	41
36	Renal function after bladderâ€preserving therapy for patients with muscleâ€invasive bladder cancer: Results of selective bladderâ€preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cystectomy. International Journal of Urology, 2019, 26, 1010-1012.	1.0	4

3

#	Article	IF	CITATIONS
37	Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. International Journal of Urology, 2019, 26, 820-826.	1.0	О
38	Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression. European Radiology, 2019, 29, 3881-3888.	4.5	20
39	Selective tetramodal bladderâ€preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscleâ€invasive bladder cancer: oncological and functional outcomes of 107 patients. BJU International, 2019, 124, 242-250.	2.5	35
40	Application of eye tracking as a user interface for urological surgery. International Journal of Urology, 2019, 26, 680-681.	1.0	2
41	Mixed reality computed tomographyâ€based surgical planning for partial nephrectomy using a headâ€mounted holographic computer. International Journal of Urology, 2019, 26, 681-682.	1.0	28
42	Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. International Journal of Urology, 2019, 26, 273-277.	1.0	11
43	Predictive ability of renal cortex enhancement in dynamic computed tomography for residual renal function after nephroureterectomy: Comparison with 99m Tcâ€diethylenetriaminopentacetic acid renography and validation study. International Journal of Urology, 2019, 26, 266-272.	1.0	3
44	Acute kidney injury and intermediateâ€ŧerm renal function after clampless partial nephrectomy. International Journal of Urology, 2019, 26, 113-118.	1.0	10
45	Association of elevated C-reactive protein with oncologic outcomes in renal CELL carcinoma: A multicenter analysis Journal of Clinical Oncology, 2019, 37, 596-596.	1.6	1
46	miRNA299 involvement in CYP11B2 expression in aldosterone-producing adenoma. European Journal of Endocrinology, 2019, 181, 69-78.	3.7	8
47	Disparities in survival outcomes in African Americans in renal cell carcinoma: Impact of oncological versus nononcological factors Journal of Clinical Oncology, 2019, 37, 595-595.	1.6	0
48	Clinical outcomes of muscle-invasive bladder cancer patients with hydronephrosis treated with tetra-modality bladder sparing therapy incorporating consolidative partial cystectomy Journal of Clinical Oncology, 2019, 37, 430-430.	1.6	0
49	Development and validation of a novel scoring index (C-reactive protein, age, race, and tumor size) to predict renal functional decline post partial nephrectomy Journal of Clinical Oncology, 2019, 37, 597-597.	1.6	0
50	Intensity ratio curve analysis of small renal masses on T2â€weighted magnetic resonance imaging: Differentiation of fatâ€poor angiomyolipoma from renal cell carcinoma. International Journal of Urology, 2018, 25, 554-560.	1.0	5
51	Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients. European Urology, 2018, 74, 46-47.	1.9	6
52	Prediction of Intraoperative Urinary Collecting System Entry in Patients with Peripheral Renal Tumors Undergoing Partial Nephrectomy: Usefulness of Tumor-Centered Multiplanar Reconstruction. Urologia Internationalis, 2018, 100, 85-91.	1.3	2
53	Adherent Perinephric Fat in Asian Patients: Predictors and Impact on Perioperative Outcomes of Partial Nephrectomy. Urologia Internationalis, 2018, 101, 437-442.	1.3	25
54	Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1408-1416.	0.8	17

#	Article	IF	CITATIONS
55	Potential for computerâ€aided diagnosis using a convolutional neural network algorithm to diagnose fatâ€poor angiomyolipoma in enhanced computed tomography and T2â€weighted magnetic resonance imaging. International Journal of Urology, 2018, 25, 978-979.	1.0	6
56	Computerâ€aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm. BJU International, 2018, 122, 411-417.	2.5	84
57	Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e1151-e1158.	1.9	41
58	Multitask Imaging Monitor for Surgical Navigation: Combination of Touchless Interface and Head-Mounted Display. Urologia Internationalis, 2017, 98, 486-488.	1.3	6
59	Local Treatment of the Prostate in Metastatic Prostate Cancer: Need to Change the Concept?. European Urology, 2017, 72, 20-21.	1.9	0
60	Utility of computed diffusionâ€weighted MRI for predicting aggressiveness of prostate cancer. Journal of Magnetic Resonance Imaging, 2017, 46, 490-496.	3.4	20
61	Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral Resection. Urologia Internationalis, 2017, 98, 298-303.	1.3	6
62	Standardization of the apparent diffusion coefficient value of bladder cancer across different centers: Applicability in predicting aggressive pathologic phenotypes. Clinical Imaging, 2017, 44, 121-126.	1.5	4
63	Realâ€time threeâ€dimensional image angle rectification to improve hand–eye coordination in singleâ€port laparoendoscopic surgery. International Journal of Urology, 2017, 24, 639-640.	1.0	2
64	Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI Diagnosis for Extracapsular Extension of Prostate Cancer. American Journal of Roentgenology, 2017, 209, W76-W84.	2.2	42
65	Stepwise algorithm using computed tomography and magnetic resonance imaging for diagnosis of fatâ€poor angiomyolipoma in small renal masses: Development and external validation. International Journal of Urology, 2017, 24, 511-517.	1.0	14
66	Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. International Journal of Clinical Oncology, 2017, 22, 1081-1086.	2.2	25
67	Absence of renal artery pseudoaneurysm on computed tomography after minimallyâ€invasive partial nephrectomy using clampless and sutureless techniques. International Journal of Urology, 2017, 24, 472-473.	1.0	9
68	Ureteral Involvement Is Associated with Poor Prognosis in Upper Urinary Tract Urothelial Carcinoma Patients Treated by Nephroureterectomy: A Multicenter Database Study. European Urology Focus, 2016, 2, 296-302.	3.1	14
69	Re: Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1a–T1b Renal Mass and Normal Preoperative Renal Function. European Urology, 2016, 69, 538.	1.9	1
70	Reply to Umberto Capitanio, Paolo Dell'Oglio, Alessandro Larcher, and Francesco Montorsi's Reply to Kazutaka Saito's Words of Wisdom re: Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1a–T1b Renal Mass and Normal Preoperative Renal Function. Eur Urol. 2016;69:538. European Urology, 2016, 70, e99.	1.9	0
71	Candidate selection for quadrantâ€based focal ablation through a combination of diffusionâ€weighted magnetic resonance imaging and prostate biopsy. BJU International, 2016, 117, 94-101.	2.5	10
72	Recovery of renal function after radical nephrectomy and risk factors for postoperative severe renal impairment: A Japanese multicenter longitudinal study. International Journal of Urology, 2016, 23, 219-223.	1.0	15

#	Article	IF	CITATIONS
73	A novel interactive educational system in the operating room–the IE system. BMC Medical Education, 2016, 16, 44.	2.4	9
74	Re: Evaluation of Functional Outcomes After Laparoscopic Partial Nephrectomy Using Renal Scintigraphy: Clamped vs. Clampless Technique. European Urology, 2016, 69, 753.	1.9	0
75	Novel threeâ€dimensional image system for transurethral surgery. International Journal of Urology, 2015, 22, 714-715.	1.0	5
76	Progression of hypertension after partial nephrectomy in patients with renal tumors: A preliminary report. International Journal of Urology, 2015, 22, 797-798.	1.0	11
77	Pharmacokinetic–Pharmacodynamic Analysis of Sunitinib-Induced Thrombocytopenia in Japanese Patients with Renal Cell Carcinoma. Biological and Pharmaceutical Bulletin, 2015, 38, 402-410.	1.4	14
78	Patient's Self-monitoring of Transurethral Surgical Images Using a Head-mounted Display. Urology Case Reports, 2015, 3, 27-29.	0.3	4
79	A Novel Approach to Surgical Instructions for Scrub Nurses by Using See-Through–Type Head-Mounted Display. CIN - Computers Informatics Nursing, 2015, 33, 335-338.	0.5	7
80	Diagnostic performance and safety of a threeâ€dimensional 14â€core systematic biopsy method. BJU International, 2015, 115, 412-418.	2.5	3
81	High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol. Clinical Genitourinary Cancer, 2015, 13, e243-e251.	1.9	22
82	A Novel Approach to Patient Selfâ€Monitoring of Sonographic Examinations Using a Headâ€Mounted Display. Journal of Ultrasound in Medicine, 2015, 34, 29-35.	1.7	7
83	Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU International, 2015, 115, 705-712.	2.5	43
84	Gasless laparoendoscopic singleâ€port clampless sutureless partial nephrectomy for peripheral renal tumors: Perioperative outcomes. International Journal of Urology, 2015, 22, 349-355.	1.0	27
85	Head-Mounted Display for a Personal Integrated Image Monitoring System: Ureteral Stent Placement. Urologia Internationalis, 2015, 94, 117-120.	1.3	19
86	Novel image monitoring system using a headâ€mounted display for assistants in da Vinci surgery. International Journal of Urology, 2015, 22, 520-521.	1.0	6
87	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Partial Nephrectomy. , 2015, , 43-64.		2
88	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Adrenalectomy., 2015,, 85-104.		1
89	Application of the RoboSurgeon System in Medical Care. , 2015, , 175-184.		0
90	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Radical Nephrectomy., 2015,, 23-42.		0

#	Article	IF	Citations
91	Gasless Single-Port RoboSurgeon Partial Cystectomy: A Hybrid Technique Combining an Intravesical and Extravesical Approach., 2015,, 143-158.		0
92	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Radical Prostatectomy., 2015, , 105-126.		0
93	Gasless Two-Port Access RoboSurgeon Retroperitoneoscopic Radical Nephroureterectomy. , 2015, , 65-84.		1
94	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Pelvic Lymph Node Dissection and Inguinal Hernia Prevention., 2015,, 159-173.		0
95	Gasless Single-Port RoboSurgeon Total Cystectomy with Urinary Diversion. , 2015, , 127-141.		1
96	AÂthree-dimensional head-mounted display system (RoboSurgeon system) for gasless laparoendoscopic single-port partial cystectomy. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 4, 638-643.	0.7	9
97	Integrated image monitoring system using head-mounted display for gasless single-port clampless partial nephrectomy. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 4, 634-637.	0.7	6
98	New head-mounted display system applied to endoscopic management of upper urinary tract carcinomas. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 842-845.	1.5	13
99	Pre-operative Risk Stratification for Cancer-specific Survival in Patients with Renal Cell Carcinoma with Venous Involvement Who Underwent Nephrectomy. Japanese Journal of Clinical Oncology, 2014, 44, 756-761.	1.3	10
100	Renal function after radical nephrectomy: Development and validation of predictive models in <scp>J</scp> apanese patients. International Journal of Urology, 2014, 21, 238-242.	1.0	23
101	Clinical Application of a Modern Highâ€Definition Headâ€Mounted Display in Sonography. Journal of Ultrasound in Medicine, 2014, 33, 1499-1504.	1.7	18
102	Bone Abnormal Signal Incidentally Found in Pre-Biopsy Diffusion-Weighted MRI for Suspected Prostate Cancer: What Does It Reflect?. Urologia Internationalis, 2014, 93, 170-175.	1.3	4
103	MP8-09 ANTIMICROBIAL PROPHYLAXIS IS AVOIDABLE IN MINIMALLY INVASIVE NEPHROURETERECTOMY WITH NEGATIVE URINE CULTURE. Journal of Urology, 2014, 191, .	0.4	1
104	Combined resection of a tumor and the inferior vena cava: report of two cases. Surgery Today, 2014, 44, 166-170.	1.5	1
105	Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer. Quality of Life Research, 2014, 23, 1641-1650.	3.1	9
106	Combination of Diffusion-weighted Magnetic Resonance Imaging and Extended Prostate Biopsy Predicts Lobes Without Significant Cancer: Application in Patient Selection for Hemiablative Focal Therapy. European Urology, 2014, 65, 186-192.	1.9	28
107	Significance of Positive Urine Cytology on Progression and Cancer-Specific Mortality of Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2014, 12, e87-e93.	1.9	12
108	Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. International Urology and Nephrology, 2014, 46, 555-561.	1.4	39

#	Article	IF	CITATIONS
109	Equivalent survival and improved preservation of renal function after distal ureterectomy compared with nephroureterectomy in patients with urothelial carcinoma of the distal ureter: A propensity scoreâ€matched multicenter study. International Journal of Urology, 2014, 21, 1098-1104.	1.0	29
110	PD13-06 FAVORABLE OUTCOMES OF GASLESS SINGLE-PORT CLAMPLESS PARTIAL NEPHRECTOMY USING NEW THREE DIMENSIONAL HEAD-MOUNTED DISPLAY SYSTEM (ROBOSURGEON SYSTEM). Journal of Urology, 2014, 191, .	0.4	2
111	Impact of bladder neck involvement on progression in patients with primary non–muscle invasive bladder cancer: A prospective validation study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 38.e29-38.e36.	1.6	18
112	Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. Journal of Magnetic Resonance Imaging, 2014, 39, 172-178.	3.4	97
113	Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 35.e1-35.e7.	1.6	3
114	External validation of TNM-C score in three community hospital cohorts for clear cell renal cell carcinoma. Anticancer Research, 2014, 34, 921-6.	1.1	2
115	Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report. European Radiology, 2013, 23, 2206-2214.	4.5	33
116	Usefulness of Pre-biopsy Multiparametric Magnetic Resonance Imaging and Clinical Variables to Reduce Initial Prostate Biopsy in Men with Suspected Clinically Localized Prostate Cancer. Journal of Urology, 2013, 190, 502-508.	0.4	65
117	Diagnostic performance of initial transperineal 14-core prostate biopsy to detect significant cancer. International Urology and Nephrology, 2013, 45, 645-652.	1.4	9
118	High Diagnostic Ability of Multiparametric Magnetic Resonance Imaging to Detect Anterior Prostate Cancer Missed by Transrectal 12-Core Biopsy. Journal of Urology, 2013, 190, 867-873.	0.4	69
119	Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients. Urology, 2013, 82, 846-851.	1.0	61
120	Successful reduction of hospital-acquired methicillin-resistant Staphylococcus aureus in a urology ward: a 10-year study. BMC Urology, 2013, 13, 35.	1.4	12
121	Role of Câ€reactive protein in urological cancers: A useful biomarker for predicting outcomes. International Journal of Urology, 2013, 20, 161-171.	1.0	55
122	Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1270-1275.	1.6	10
123	49 THE ABNORMALITY OF GLUCOSE TOLERANCE TEST IN PHEOCHROMOCYTOMA: ONE OF THE SIGNIFICANT FINDINGS OF POSTOPERATIVE HYPOGLYCEMIA. Journal of Urology, 2013, 189, .	0.4	1
124	840 NEW THREE-DIMENSIONAL HEAD-MOUNTED DISPLAY SYSTEM (ROBOSURGEON SYSTEM): APPLICATION TO THE INITIAL 80 CASES OF GASLESS SINGLE-PORT ACCESS UROLOGIC SURGERIES. Journal of Urology, 2013, 189, .	0.4	12
125	Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. International Journal of Clinical Oncology, 2013, 18, 884-889.	2.2	41
126	CRP kinetics could be prognostic predictors in urothelial cancer. Nature Reviews Urology, 2013, 10, 182-182.	3.8	0

#	Article	IF	Citations
127	Impact of Advanced Age on Biochemical Recurrence After Radical Prostatectomy in Japanese Men According to Pathological Stage. Japanese Journal of Clinical Oncology, 2013, 43, 410-416.	1.3	12
128	Diabetes Mellitus with Obesity is a Predictor of Recurrence in Patients with Non-metastatic Renal Cell Carcinoma. Japanese Journal of Clinical Oncology, 2013, 43, 740-746.	1.3	17
129	Impact of lower urinary tract symptoms on prostate cancer risk among <scp>J</scp> apanese men with prostateâ€specific antigen <10 ng/mL and nonâ€suspicious digital rectal examination. International Journal of Urology, 2013, 20, 1163-1168.	1.0	5
130	Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. British Journal of Cancer, 2012, 107, 1031-1036.	6.4	28
131	Editorial Comment from Dr Saito to Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. International Journal of Urology, 2012, 19, 1059-1059.	1.0	0
132	Role of Diffusion-Weighted Magnetic Resonance Imaging in Predicting Sensitivity to Chemoradiotherapy in Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, e21-e27.	0.8	112
133	1105 GASLESS SINGLE-PORT CLAMPLESS PARTIAL NEPHRECTOMY FOR PERIPHERAL RENAL TUMOR SURGICAL, SHORT-TERM ONCOLOGICAL, AND FUNCTIONAL OUTCOMES. Journal of Urology, 2012, 187, .	0.4	1
134	Effect of Diabetes Mellitus on High-grade Prostate Cancer Detection Among Japanese Obese Patients With Prostate-specific Antigen Less Than 10 ng/mL. Urology, 2012, 79, 1329-1335.	1.0	12
135	Antimicrobial Prophylaxis is Not Necessary in Clean Category Minimally Invasive Surgery for Renal and Adrenal Tumors: A Prospective Study of 373 Consecutive Patients. Urology, 2012, 80, 570-575.	1.0	25
136	Gasless Single Port Surgery for Renal Cell Carcinoma: Minimum Incision Endoscopic Surgery. , 2012, , .		1
137	Diagnostic contribution of C-reactive protein kinetics for gastric metastasis from renal cell carcinoma. International Cancer Conference Journal, 2012, 1, 93-95.	0.5	2
138	New three-dimensional head-mounted display system, TMDU-S-3D system, for minimally invasive surgery application: Procedures for gasless single-port radical nephrectomy. International Journal of Urology, 2012, 19, 886-889.	1.0	60
139	Performance of prostateâ€specific antigen mass in estimation of prostate volume in Japanese men with benign prostate hyperplasia. International Journal of Urology, 2012, 19, 929-935.	1.0	2
140	Selective bladderâ€sparing protocol consisting of induction lowâ€dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscleâ€invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU International, 2012, 109, 860-866.	2.5	55
141	Characteristics and clinical significance of prostate cancers missed by initial transrectal 12â€core biopsy. BJU International, 2012, 109, 665-671.	2.5	36
142	Pathologyâ€based risk stratification of muscleâ€invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladderâ€sparing approaches. BJU International, 2012, 110, E203-8.	2.5	12
143	Prostateâ€specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castrationâ€resistant prostate cancer. BJU International, 2012, 110, 1149-1155.	2.5	10
144	Impact of Câ€reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by secondâ€line chemotherapy with gemcitabine, etoposide and cisplatin. BJU International, 2012, 110, 1478-1484.	2.5	28

#	Article	IF	CITATIONS
145	Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer. BJU International, 2012, 110, E564-9.	2.5	9
146	A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasia. Asian Journal of Andrology, 2012, 14, 703-707.	1.6	8
147	1172 ANTIBIOTIC PROPHYLAXIS IS NOT NECESSARY IN MINIMALLY INVASIVE SURGERY FOR RENAL AND ADRENAL TUMORS: A PROSPECTIVE STUDY OF 301 CONSECUTIVE PATIENTS. Journal of Urology, 2011, 185, .	0.4	1
148	C-reactive protein as a biomarker for urological cancers. Nature Reviews Urology, 2011, 8, 659-666.	3.8	105
149	A Novel Repeat Biopsy Nomogram Based on Three-dimensional Extended Biopsy. Urology, 2011, 77, 915-920.	1.0	6
150	Young Age as Favorable Prognostic Factor for Cancer-specific Survival in Localized Renal Cell Carcinoma. Urology, 2011, 77, 842-847.	1.0	24
151	Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel. Urology, 2011, 78, 1131-1135.	1.0	46
152	Longitudinal Change in Renal Function After Radical Nephrectomy in Japanese Patients With Renal Cortical Tumors. Journal of Urology, 2011, 185, 2066-2071.	0.4	34
153	Diffusionâ€weighted magnetic resonance imaging in the differentiation of angiomyolipoma with minimal fat from clear cell renal cell carcinoma. International Journal of Urology, 2011, 18, 727-730.	1.0	58
154	Phaseâ€II trial of combination treatment of interferonâ€Î±, cimetidine, cyclooxygenaseâ€2 inhibitor and reninâ€angiotensinâ€system inhibitor (l CA therapy) for advanced renal cell carcinoma. Cancer Science, 2011, 102, 137-143.	3.9	33
155	Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. European Radiology, 2011, 21, 2178-2186.	4.5	157
156	Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clinical and Experimental Metastasis, 2011, 28, 405-411.	3.3	25
157	Perioperative Complications of Radical Cystectomy After Induction Chemoradiotherapy in Bladder-sparing Protocol Against Muscle-invasive Bladder Cancer: A Single Institutional Retrospective Comparative Study with Primary Radical Cystectomy. Japanese Journal of Clinical Oncology, 2011, 41, 1373-1379.	1.3	30
158	Interactions between inducible nitric oxide synthase and cyclooxygenaseâ€2 in response to ischaemiaâ€reperfusion of rabbit bladder. BJU International, 2010, 106, 716-722.	2.5	4
159	Editorial Comment to Nomogram to predict seminal vesicle invasion using the status of cancer at the base of the prostate on systematic biopsy. International Journal of Urology, 2010, 17, 540-540.	1.0	0
160	Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 1979-1989.	2.4	37
161	Initial Experience of Diffusion-weighted Magnetic Resonance Imaging to Assess Therapeutic Response to Induction Chemoradiotherapy Against Muscle-invasive Bladder Cancer. Urology, 2010, 75, 387-391.	1.0	97
162	Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma. European Urology, 2009, 55, 1145-1154.	1.9	104

#	Article	IF	CITATIONS
163	Discarding antimicrobial prophylaxis for transurethral resection of bladder tumor: A feasibility study. International Journal of Urology, 2009, 16, 61-63.	1.0	18
164	Safety of transperineal 14â€core systematic prostate biopsy in diabetic men. International Journal of Urology, 2009, 16, 930-935.	1.0	25
165	Favourable outcomes of patients with clinical stage T3NOMO bladder cancer treated with induction lowâ€dose chemoâ€radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a singleâ€institutional retrospective comparative study. BJU International, 2009, 104, 189-194.	2.5	40
166	Development and External Validation of a New Outcome Prediction Model for Patients With Clear Cell Renal Cell Carcinoma Treated With Nephrectomy Based on Preoperative Serum C-Reactive Protein and TNM Classification: The TNM-C Score. Journal of Urology, 2009, 181, 1004-1012.	0.4	87
167	Oncological outcome of minimum incision endoscopic radical nephrectomy for pathologically organ confined renal cell carcinoma. International Journal of Urology, 2008, 15, 44-47.	1.0	13
168	Collecting duct carcinoma with acquired cystic disease of the kidney in a longâ€term hemodialysis patient. International Journal of Urology, 2008, 15, 93-95.	1.0	3
169	Initial experience of functional imaging of upper urinary tract neoplasm by diffusionâ€weighted magnetic resonance imaging. International Journal of Urology, 2008, 15, 140-143.	1.0	39
170	Female urethral diverticular abscess clearly depicted by diffusionâ€weighted magnetic resonance imaging. International Journal of Urology, 2008, 15, 460-461.	1.0	7
171	Favorable response to combination treatment of cimetidine, cyclooxygenaseâ€2 inhibitor and reninâ€angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases. International Journal of Urology, 2008, 15, 848-850.	1.0	8
172	Threeâ€dimensional 26â€core biopsyâ€based patient selection criteria for nerveâ€sparing radical prostatectomy. International Journal of Urology, 2008, 15, 1061-1066.	1.0	7
173	History of malignancy is a predictor of prostate cancer detection: Incorporation into a preâ€biopsy nomogram. International Journal of Urology, 2008, 15, 1055-1060.	1.0	8
174	Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU International, 2008, 101, 775-780.	2.5	87
175	Câ€reactive protein level predicts prognosis in patients with muscleâ€invasive bladder cancer treated with chemoradiotherapy. BJU International, 2008, 101, 978-981.	2.5	63
176	Development, Validation, and Head-to-Head Comparison of Logistic Regression-Based Nomograms and Artificial Neural Network Models Predicting Prostate Cancer on Initial Extended Biopsy. European Urology, 2008, 54, 601-611.	1.9	80
177	Low-Dose Chemoradiotherapy Followed by Partial or Radical Cystectomy Against Muscle-Invasive Bladder Cancer: An Intent-to-Treat Survival Analysis. Urology, 2008, 72, 384-388.	1.0	40
178	Incidence of Benign Pathologic Lesions at Partial Nephrectomy for Presumed RCC Renal Masses: Japanese Dual-Center Experience with 176 Consecutive Patients. Urology, 2008, 72, 598-602.	1.0	127
179	Prognostic Impact of Postoperative C-Reactive Protein Level in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy. Journal of Urology, 2008, 180, 515-519.	0.4	59
180	External Validation of the Mayo Clinic Cancer Specific Survival Score in a Japanese Series of Clear Cell Renal Cell Carcinoma. Journal of Urology, 2008, 180, 1290-1296.	0.4	34

#	Article	lF	CITATIONS
181	Lymphovascular Invasion is Independently Associated With Poor Prognosis in Patients With Localized Upper Urinary Tract Urothelial Carcinoma Treated Surgically. Journal of Urology, 2007, 178, 2291-2296.	0.4	61
182	Increased preoperative serum Câ€reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU International, 2007, 99, 77-80.	2.5	103
183	The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU International, 2007, 100, 269-273.	2.5	88
184	Spatial and Isoform Specific p63 Expression in the Male Human Urogenital Tract. Journal of Urology, 2006, 176, 2268-2273.	0.4	14
185	Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU International, 2006, 97, 1322-1326.	2.5	25
186	Possible involvement of bone morphogenetic protein 2 in heterotopic ossification in metastatic lesion from urothelial carcinoma of bladder. International Journal of Urology, 2006, 13, 1126-1128.	1.0	24
187	Prognostic Significance of Endothelial Per-Arnt-Sim Domain Protein 1/Hypoxia-Inducible Factor-2α Expression in a Subset of Tumor Associated Macrophages in Invasive Bladder Cancer. Journal of Urology, 2004, 171, 1080-1084.	0.4	29
188	LOCALIZATION OF AQUAPORIN-7 IN HUMAN TESTIS AND EJACULATED SPERM: POSSIBLE INVOLVEMENT IN MAINTENANCE OF SPERM QUALITY. Journal of Urology, 2004, 172, 2073-2076.	0.4	73
189	Favorable Outcome of Preoperative Low Dose Chemoradiotherapy Against Muscle-Invasive Bladder Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 504-507.	1.3	13
190	Increased expression of sialyl-Lewis A correlates with poor survival in upper urinary tract urothelial cancer patients. Anticancer Research, 2003, 23, 3441-6.	1.1	12
191	Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clinical Cancer Research, 2003, 9, 5501-7.	7.0	115
192	Endoscope-assisted Minilaparotomy (Endoscopic Minilaparotomy) for Retroperitoneal Schwannoma: Experience with Three Cases. Japanese Journal of Clinical Oncology, 2002, 32, 177-180.	1.3	13
193	Endoscopic Minilaparotomy Partial Nephrectomy for Solitary Renal Cell Carcinoma Smaller than 4 cm. Japanese Journal of Clinical Oncology, 2002, 32, 417-421.	1.3	10
194	Malignant Clear Cell "Sugar―Tumor of the Kidney: Clear Cell Variant of Epithelioid Angiomyolipoma. Journal of Urology, 2002, 168, 2533-2534.	0.4	41
195	IFNy enhances the cytotoxicity of 5-fluorouracil against human bladder cancer cells through induction of PD-ECGF / TP. Japanese Journal of Urology, 2002, 93, 323.	0.1	0
196	Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in primary bladder cancer. Japanese Journal of Urology, 2002, 93, 377.	0.1	0
197	Malignant clear cell "sugar" tumor of the kidney: clear cell variant of epithelioid angiomyolipoma. Journal of Urology, 2002, 168, 2533-4.	0.4	11